Recognition of uridine diphosphate glucuronosyl transferases by LKM-3 antibodies in chronic hepatitis D

doi:10.1016/S0140-6736(94)91966-6

The Lancet

Volume 344, Issue 8922, 27 August 1994, Pages 578-581

https://doi.org/10.1016/S0140-6736(94)91966-6 Get rights and content

Abstract

Summary

Patients with chronic hepatitis D often have liver-kidney microsomal antibodies type 3 (LKM-3). These antibodies react with several microsomal antigens that have a molecularweight of 55 KDa and an isoelectric point of about 8.

We studied the molecular nature of the antigen and, by immunoscreening a human liver cDNA expression library with KM-3 sera, found that uridine diphosphate glucuronosyl transferases (UGT) appeared as candidate antigens. We confirmed the identity of UGT as an antigen by reacting the sera with recombinant rabbit liver UGT proteins. Some sera reacted with rabbit UGT-2 proteins, but UGT-1 proteins were more sensitive and specific in detecting LKM-3 autoantibodies in patient sera. Anti-UGT-1 antibodies were detected in all LKM-3 positive sera from patients with hepatitis D and 1 out of 11 patients with autoimmune hepatitis type 2. Sera from patients who had hepatitis B only did not react with UGT proteins.

The UGT proteins are part of the phase II enzymes of drug metabolism and are the first such enzymes to be identified as human autoantigens.

References (33)

D. Vergani et al.
Type II autoimmune hepatitis. What is the role of the hepatitis C virus
Gastroenterology
(1993)
Mp Manns et al.
Identification of cytochrome P450 IA2 as human autoantigen
Arch Biochem Biophys
(1990)
PH. O'Farrell
High resolution two-dimensional electrophoresis of proteins
J Biol Chem
(1975)
Rh Tukey et al.
Cloning and characterization of rabbit liver UDP-glucuronosyltransferase cDNAs
J Biol Chem
(1993)
Rl Norman et al.
Identification of the major cytochrome P-450 form transplacentally induced in neonatal rabbits by 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin
J Biol Chem
(1978)
P. Straub et al.
Cassette mutagenesis of a potential substrate recognition region of cytochrome P450 2C2
J Biol Chem
(1993)
Jk Ritter et al.
A novel complex locus UGT1 encodes human bilirubin, phenol, and other UDP-glucuronosyltransferase isozymes with identical carboxyl termini
J Biol Chem
(1992)
Pi Mackenzie et al.
Organization of the rat UDP-glucuronosyltransferase, UDPGTr-2, gene and characterization of its promoter
J Biol Chem
(1990)
Pi Mackenzie et al.
Steroid UDP glucuronosyltransferases
J Steroid Biochem Mol Biol
(1992)
T. Iyanagi et al.
Cloning and characterization of cDNA endcoding methylcholantrene inducible rat mRNA for UDP-glucuronosyltransferase
J Biol Chem
(1986)

L. Sutherland et al.

Characterization of a human bilirubin UDP-glucuronosyltransferase stably expressed in hamster lung fibroblast cell cultures

FEBS Lett

(1992)

Pj Bosma et al.

A mutation in bilirubin uridine 5'-diphosphate-glucuronosyltransferase isoform 1 causing Crigler-Najjar syndrome type II

Gastroenterology

(1993)

M. Manns et al.

Major antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450 dbl

J Clin Invest

(1989)

Um Zanger et al.

Antibodies against human cytochrome P-450 dbl in autoimmune hepatitis type II

Proc Natl Acad Sci USA

(1988)

Mp Manns et al.

LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase

J Clin Invest

(1991)

Mj Amengual et al.

Autoantibodies in chronic delta virus infection recognize a common protein of 46 kD in rat forestomach basal cell layer and stellate thymic epithelial cells

Clin Exp Immunol

(1989)

Cited by (121)

The clinical usage and definition of autoantibodies in immune-mediated liver disease: A comprehensive overview
2018, Journal of Autoimmunity
Autoimmune serology is key to the diagnosis and management of autoimmune liver diseases. Its correct use in clinical practice requires a basic knowledge of the laboratory techniques used for autoantibody detection. Indirect immunofluorescence (IIF) on triple rodent tissue is still the gold standard screening procedure for liver-relevant autoantibodies, while HEp2 cells and human ethanol-fixed neutrophils are used as substrates to characterize nuclear reactivities and to detect anti-neutrophil cytoplasm antibody, respectively. Assays based on purified or recombinant antigens are increasingly used, having the main advantage of being observer-independent and the disadvantage of detecting only autoantibodies whose antigenic target has been identified. The AIH-specific anti-soluble liver antigen antibody cannot be detected by IIF and a molecular-based assay should be used at the screening level. Since autoantibodies may be present in the context of viral hepatitides and other inflammatory liver diseases it is important to exclude these conditions before diagnosing autoimmune liver disease. Anti-nuclear antibody (ANA), most often with a homogeneous IIF pattern on HEp2 cells, characterizes type 1 autoimmune hepatitis (AIH), and is found in association with anti-smooth muscle antibody in about half of the cases. Two IIF ANA patterns are specific for primary biliary cholangitis, namely the rim-like/membranous pattern, and the multiple nuclear dots pattern. Anti-liver kidney microsomal antibody type 1 is the serological hallmark of type 2 AIH, often in association with anti-liver cytosol type 1 antibody. Atypical perinuclear anti-neutrophil antibody, referred to as perinuclear anti-neutrophil nuclear antibody, is frequently detected in primary sclerosing cholangitis, in AIH type 1 and in inflammatory bowel diseases. The anti-asiaglycoprotein receptor antibody is liver-specific but not disease-specific, and reliable commercial assays for its detection are lacking. Anti-mitochondrial antibody is the hallmark of primary biliary cholangitis (PBC), being disease-specific and present in about 95% of the PBC patients. Its incidental detection presages the future development of PBC.
Cutting edge issues in autoimmune hepatitis
2016, Journal of Autoimmunity
Citation Excerpt :
Importantly, anti-SLA are detectable by ELISA or radio-immuno-assays, but not by immunofluorescence [82,84]. Anti-LKM-3 antibodies, directed to family 1 of UDP-glycuronosyl transferases (UGT1), are a further marker for AIH-2 [85,86], and may also be the only serological maker for AIH. Liver histology is essential to confirm the diagnosis of AIH, as highlighted in all diagnostic scoring systems [10,11].
Autoimmune hepatitis (AIH) is a severe liver disease affecting all age groups worldwide. Novel basic and clinical aspects of AIH, addressed at a Monothematic Conference in London in September 2015, are highlighted in this review. The diagnosis of AIH relies upon detection of characteristic autoantibodies, hypergammaglobulinemia, and interface hepatitis on liver histology. The International Autoimmune Hepatitis Group (IAIHG) has devised diagnostic scoring systems to help in comparative studies and clinical practice. AIH arises in a genetically predisposed host, when yet unknown triggers – such an encounter with a pathogen – lead to a T cell-mediated immune response targeting liver autoantigens. This immune response is inadequately controlled because regulatory mechanisms are impaired. The mainstay of treatment for AIH is immunosuppression, which should be instituted as soon as the diagnosis is made. Standard treatment regimens include relatively high doses of predniso(lo)ne, which are tapered gradually as azathioprine is introduced. Recent guidelines have described newer treatment regimens and have tightened the goal of therapy to complete normalization of biochemical, serological and histological parameters. Mycophenolate mofetil, calcineurin inhibitors, mTOR inhibitors and biological agents are potential salvage therapies, but should be reserved for selected non-responsive patients and administered only in experienced centers. Liver transplantation is a life-saving option for those patients who progress to end-stage liver disease. Further dissection of cellular and molecular pathways involved in AIH pathogenesis is likely to lead to the discovery of novel, tailored and better tolerated therapies.
Autoimmune hepatitis - Update 2015
2015, Journal of Hepatology
Citation Excerpt :
This drug was withdrawn from clinical use in 1980. Anti-LKM3 antibodies are specific for members of the uridine glucuronosyltransferase family 1 [43] and give an immunofluorescence pattern similar to anti-LKM1 [44]. Although anti-LKM3 is most commonly detected in patients with hepatitis D (delta), it is also present in some 10% of patients with AIH-2 and in some cases may be the only serological marker of AIH [45].
Viral Hepatitis
2014, Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases
Clinical significance of autoantibodies in autoimmune hepatitis
2013, Journal of Autoimmunity
The accurate diagnosis and classification of autoimmune hepatitis (AIH) rely upon the detection of characteristic autoantibodies. Positivity for anti-nuclear (ANA) and/or anti-smooth muscle (SMA) autoantibodies defines AIH type 1 (AIH-1), whereas anti-liver kidney microsomal type 1 (anti-LKM1) and/or anti-liver cytosol type 1 (anti-LC1) define AIH type 2 (AIH-2). ANA and SMA, and less commonly anti-LKM1, have also been detected in de-novo autoimmune hepatitis developing after liver transplantation, a condition that may affect patients transplanted for non-autoimmune liver disease. The diagnostic autoantibodies associated with AIH-1 are also detected in the paediatric AIH/sclerosing cholangitis overlap syndrome, referred to as autoimmune sclerosing cholangitis (ASC). ASC, like adult primary sclerosing cholangitis, is often associated with atypical perinuclear anti-neutrophil cytoplasmic autoantibodies (p-ANCA), although p-ANCA are also detected in other autoimmune liver diseases. These associations highlight the necessity for simple and prompt diagnostic autoantibody testing, and the requirement for the accurate interpretation of the results of the tests in the clinical context. Fine-mapping of antigenic autoantibody targets has facilitated the development of rapid molecular assays that have the potential to revolutionise the field if properly standardised and when used in combination with classical immunofluorescence. Despite their diagnostic significance, the pathogenic role of the various autoantibodies and the mechanisms by which they can potentially inflict damage onto the liver cell remain a topic for further research.
Autoimmune Hepatitis
2012, Zakim and Boyer's Hepatology

View all citing articles on Scopus

View full text

ArticlesRecognition of uridine diphosphate glucuronosyl transferases by LKM-3 antibodies in chronic hepatitis D

Abstract

Gastroenterology

Arch Biochem Biophys

J Biol Chem

J Biol Chem

J Biol Chem

J Biol Chem

J Biol Chem

J Biol Chem

J Steroid Biochem Mol Biol

J Biol Chem

FEBS Lett

Gastroenterology

Major antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450 dbl

J Clin Invest

Antibodies against human cytochrome P-450 dbl in autoimmune hepatitis type II

Proc Natl Acad Sci USA

LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase

J Clin Invest

Autoantibodies in chronic delta virus infection recognize a common protein of 46 kD in rat forestomach basal cell layer and stellate thymic epithelial cells

Clin Exp Immunol

Articles
Recognition of uridine diphosphate glucuronosyl transferases by LKM-3 antibodies in chronic hepatitis D